

## SELECTED DEVELOPMENT PROJECTS

Compound/ product	Common name	Mechanism of action	Potential indication	Category	Formulation/ route of administration	Year project entered current development phase	Planned filing dates/current phase
AVXS-101 (OAV101)	onasemnogene abeparvovec	Survival motor neuron (SMN) gene therapy	Spinal muscular atrophy (IT formulation)	Neuroscience	Intrathecal injection	2021	2025/III
<i>Beovu</i>	brolocizumab	VEGF inhibitor	Diabetic retinopathy	Ophthalmology	Intravitreal injection	2020	2025/III
CFZ533	iscalimab	CD40 inhibitor	Sjögren's syndrome	Immunology	Subcutaneous injection	2019	≥2027/II
<i>Coartem</i>	artemether + lumefantrine	PGH-1 (artemisinin combination therapy)	Malaria, uncomplicated (<5 kg patients)	Global Health	Oral	2020	2024/III
<i>Cosentyx</i>	secukinumab	IL-17A inhibitor	Giant cell arteritis	Immunology	Subcutaneous injection	2021	2025/III
			Polymyalgia rheumatica <sup>1</sup>	Immunology	Subcutaneous injection	2023	2026/III
			Rotator cuff tendinopathy <sup>1</sup>	Immunology	Subcutaneous injection	2023	≥2027/III
EXV811 <sup>1</sup>	atrasentan	ETA receptor antagonist	IgA nephropathy	Cardiovascular, Renal and Metabolic	Oral	2023	2024/III
<i>Fabhalta</i>	iptacopan	CFB inhibitor	IgA nephropathy	Cardiovascular, Renal and Metabolic	Oral	2021	2024/III
			C3 glomerulopathy	Cardiovascular, Renal and Metabolic	Oral	2021	2024/III
			IC-MPGN <sup>1</sup>	Cardiovascular, Renal and Metabolic	Oral	2023	≥2027/III
			Atypical hemolytic uremic syndrome	Oncology	Oral	2021	≥2027/III
FUB523 <sup>1</sup>	zigakibart	Anti-APRIL monoclonal antibody	IgA nephropathy	Cardiovascular, Renal and Metabolic	Subcutaneous injection	2023	≥2027/III
JDQ443	opnurasib	KRAS inhibitor	Non-small cell lung cancer <sup>2</sup> (monotherapy and/or combination therapy)	Oncology	Oral	2022	≥2027/III
KAE609	cipargamin	PfATP4 inhibitor	Malaria, uncomplicated	Global Health	Oral	2017	≥2027/II
			Malaria, severe	Global Health	Oral	2022	≥2027/II
<i>Kisqali</i>	ribociclib	CDK4 inhibitor	Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (adjuvant)	Oncology	Oral	2023	US, EU registration
KLU156 <sup>3</sup>	ganaplacide + lumefantrine	Non-artemisinin plasmodium falciparum inhibitor	Malaria, uncomplicated	Global Health	Oral	2023	2026/II
<i>Leqvio</i>	inclisiran	siRNA (regulation of LDL-C)	Secondary prevention of cardiovascular events in patients with elevated levels of LDL-C	Cardiovascular, Renal and Metabolic	Subcutaneous injection	2018	≥2027/III
			Primary prevention cardiovascular <sup>1</sup> risk reduction	Cardiovascular, Renal and Metabolic	Subcutaneous injection	2023	≥2027/III
LNA043	TBD	ANGPTL3 agonist	Osteoarthritis <sup>4</sup>	Immunology	Intra-articular	2021	≥2027/II
LOU064	remibrutinib	BTK inhibitor	Chronic spontaneous urticaria	Immunology	Oral	2021	2024/III
			Chronic inducible urticaria	Immunology	Oral	2023	≥2027/III
			Multiple sclerosis	Neuroscience	Oral	2021	≥2027/III
<i>Lutathera</i>	lutetium Lu 177 dotatate/ lutetium ( <sup>177</sup> Lu) oxodotreotide	Radioligand therapy targeting SSTR	Gastroenteropancreatic neuroendocrine tumors, 1 <sup>st</sup> line in G2/3 tumors	Oncology	Intravenous infusion	2020	2024/III
LXE408	TBD	Proteasome inhibitor	Visceral leishmaniasis	Global Health	Oral	2022	≥2027/II
<i>Pluvicto</i>	lutetium Lu 177 vipivotide tetraxetan/ lutetium ( <sup>177</sup> Lu) vipivotide tetraxetan	Radioligand therapy targeting PSMA	Metastatic castration-resistant prostate cancer, pre-taxane	Oncology	Intravenous infusion	2021	2024/III
			Metastatic hormone-sensitive prostate cancer	Oncology	Intravenous infusion	2021	2025/III

<sup>1</sup> Project added to selected development projects table in 2023 – entered Confirmatory Development

<sup>2</sup> Previously disclosed as non-small cell lung cancer, 2/3L

<sup>3</sup> Project added to selected development projects table in 2023 (replacing KAF156) – entered Confirmatory Development, PPFV in Phase III expected in early 2024

<sup>4</sup> Previously disclosed as knee osteoarthritis

Compound/ product	Common name	Mechanism of action	Potential indication	Category	Formulation/ route of administration	Year project entered current development phase	Planned filing dates/current phase
QGE031	ligelizumab	IgE inhibitor	Food allergy	Immunology	Subcutaneous injection	2021	≥2027/III
Scemblix	asciminib	BCR-ABL inhibitor	Chronic myeloid leukemia, 1 <sup>st</sup> line	Oncology	Oral	2021	2024/III
TQJ230	pelacarsen	ASO targeting lipoprotein(a)	Secondary prevention of cardiovascular events in patients with elevated levels of lipoprotein(a)	Cardiovascular, Renal and Metabolic	Subcutaneous injection	2019	2025/III
VAY736	ianalumab	BAFF-R inhibitor	Autoimmune hepatitis	Immunology	Subcutaneous injection	2018	≥2027/II
			Lupus nephritis	Immunology	Subcutaneous injection	2022	≥2027/III
			Sjögren's syndrome	Immunology	Subcutaneous injection	2022	2026/III
			Systemic lupus erythematosus <sup>1</sup>	Immunology	Subcutaneous injection	2023	≥2027/III
			Warm autoimmune hemolytic anemia (wAIHA)	Oncology	Intravenous infusion	2022	2026/III
			Immune thrombocytopenia, 1 <sup>st</sup> line <sup>1</sup>	Oncology	Intravenous infusion	2023	2026/III
			Immune thrombocytopenia, 2 <sup>nd</sup> line <sup>1</sup>	Oncology	Intravenous infusion	2023	2026/III
Vijoice	alpelisib	PI3K-alpha inhibitor	Lymphatic malformations	Oncology	Oral	2023	≥2027/III
Xolair	omalizumab	IgE inhibitor	Food allergy	Immunology	Subcutaneous injection	2019	US registration
XXB750	TBD	NPR1 agonist	Hypertension	Cardiovascular, Renal and Metabolic	Subcutaneous injection	2022	≥2027/II
YTB323 <sup>1</sup>	rapcabtagene autoleucel	CD19 CAR-T	Severe refractory lupus nephritis/systemic lupus erythematosus	Immunology	Intravenous infusion	2023	≥2027/II
			High-risk large B-cell lymphoma, 1 <sup>st</sup> line	Oncology	Intravenous infusion	2023	≥2027/II

<sup>1</sup> Project added to selected development projects table in 2023 – entered Confirmatory Development

## PROJECTS REMOVED FROM THE DEVELOPMENT TABLE SINCE 2022

Compound/product	Potential indication	Change	Reason
Cosentyx	Hidradenitis suppurativa	Commercialized	
	Lupus nephritis	Removed	Development discontinued
	Psoriatic arthritis (IV formulation)	Commercialized	
	Ankylosing spondylitis (IV formulation)	Commercialized	
Fabhalta	Paroxysmal nocturnal hemoglobinuria	Commercialized	
KAF156	Malaria, uncomplicated	Removed	Development discontinued <sup>1</sup>
LOU064	Sjögren's syndrome	Removed	Development discontinued
MBG453	Myelodysplastic syndrome	Removed	Development discontinued
	Unfit acute myeloid leukemia	Removed	Development discontinued
MIJ821	Major depressive disorder	Removed	Development discontinued
NIS793	Pancreatic cancer, 1 <sup>st</sup> line	Removed	Development discontinued
Piqray	Ovarian cancer	Removed	Development discontinued
PPY988	Geographic atrophy	Removed	Development discontinued
SAF312	Chronic ocular surface pain	Removed	Development discontinued
SKO136	Coronavirus infection	Removed	Development discontinued
VDT482	Esophageal cancer, 2 <sup>nd</sup> line	Removed	Development discontinued <sup>2</sup>
	Non-small cell lung cancer	Removed	Development discontinued <sup>2</sup>
	Nasopharyngeal carcinoma, 1 <sup>st</sup> line	Removed	Development discontinued <sup>2</sup>
	Gastric cancer, 1 <sup>st</sup> line	Removed	Development discontinued <sup>2</sup>
	Esophageal cancer, 1 <sup>st</sup> line	Removed	Development discontinued <sup>2</sup>
	Localized esophageal cancer	Removed	Development discontinued <sup>2</sup>
	Hepatocellular carcinoma, 1 <sup>st</sup> line	Removed	Development discontinued <sup>2</sup>
	Small cell lung cancer, 1 <sup>st</sup> line	Removed	Development discontinued <sup>2</sup>
	Urothelial cell carcinoma, 1 <sup>st</sup> line	Removed	Development discontinued <sup>2</sup>
VPM087	Colorectal cancer, 1 <sup>st</sup> line	Removed	Development discontinued

<sup>1</sup> Now in development as KLU156

<sup>2</sup> Mutual termination of the agreement with BeiGene, Ltd.